

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Odevixibat (A 4250) for treating progressive familial intrahepatic cholestasis ID1570

## Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Albireo (obeixibat)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Sick Children</li> <li>• Addenbrookes Liver Transplant Association</li> <li>• British Liver Trust</li> <li>• Children's Liver Disease Foundation</li> <li>• Contact</li> <li>• Find a Cure</li> <li>• Liver4Life</li> <li>• Muslim Council of Great Britain</li> <li>• National Children's Bureau</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for the Study of the Liver</li> <li>• British Blood Transfusion Society</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatric Society</li> <li>• British Liver Nurses Forum</li> <li>• British Society for Haematology</li> <li>• British Society of Gastroenterology</li> <li>• British Society of Paediatric Gastroenterology, Hepatology and Nutrition</li> <li>• British Transplantation Society</li> <li>• NHS Blood and Transplant</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Hospital Information Services - Jehovah's Witnesses</li> <li>• Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• National Services Division (specialised services in Scotland)</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Hepato-Biliary Group</li> <li>• Foundation for Liver Research</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• UK National Screening Committee</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics and Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• Addenbrooke's Lysosomal Disorders Unit</li> <li>• Birmingham Children's Hospital NHS Foundation Trust Lysosomal Storage Disorders Unit</li> <li>• Department of Endocrinology, University Hospital Birmingham Foundation Trust</li> <li>• Great Ormond Street Hospital Metabolic Unit</li> <li>• NHS Dudley CCG</li> <li>• NHS Kingston CCG</li> <li>• Royal Free Lysosomal Storage Disorders Unit</li> <li>• Salford Royal NHS Foundation Trust Mark Holland Metabolic Unit</li> <li>• Welsh Government</li> <li>• Willink Unit, Genetic Medicine, Central Manchester Foundation Trust</li> </ul>	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the provisional stakeholder list and which organisations, we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

## Definitions:

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.